Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial

Patricia J. A. M. Brouwers*, Erik van Werkhoven, Harry Bartelink, Alain Fourquet, Claire Lemanski, Judith van Loon, John H. Maduro, Nicola S. Russell, Luc J. E. E. Scheijmans, Dominic A. X. Schinagl, Antonia H. Westenberg, Philip Poortmans, Liesbeth J. Boersma, Young Boost Trial research group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose: In the Young Boost trial (YBT), breast cancer patients

Methods: From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomized. CO was scored subjectively by the patient and physician, and objectively using BCCT.core: at baseline, one and four years after treatment. Associations between potential risk factors for worse cosmetic outcome, based on the objective BCCT. core, were investigated using a proportional odds model.

Results: At four years, CO was significantly better in the standard boost group for all three scoring methods (satisfied CO +/- 65% vs 55%). A photon boost, high boost dose, poor cosmesis before radiation therapy, large boost volume and adjuvant chemotherapy significantly deteriorated CO.

Conclusion: Important risk factors for worse CO were the use of a photon boost instead of an electron boost, a high boost dose, cosmesis at baseline, adjuvant chemotherapy and boost volume. These results can be used to define strategies aimed at improving CO. (C) 2018 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)434-441
Number of pages8
JournalRadiotherapy and Oncology
Volume128
Issue number3
DOIs
Publication statusPublished - Sept 2018

Keywords

  • Breast conserving therapy
  • Cosmetic outcome
  • Fibrosis
  • Young patients
  • Young boost trial
  • SIMULTANEOUS INTEGRATED BOOST
  • INTENSITY-MODULATED RADIOTHERAPY
  • NO BOOST
  • RADIATION-THERAPY
  • TUMOR BED
  • CONFORMAL RADIOTHERAPY
  • CONSERVATIVE TREATMENT
  • RANDOMIZED-TRIALS
  • EORTC BOOST
  • FOLLOW-UP

Cite this